The DYNLT1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji Burkitt’s lymphoma B lymphocyte line, designed for loss-of-function studies of the DYNLT1 gene. This heterogeneous pool enables investigation of dynein light chain Tctex-1 biology without clonal selection artifacts; the polyclonal nature captures a range of editing outcomes, providing a robust model for functional genomics and phenotypic screening in B-cell research.
The Raji cell line is a well-characterized Epstein?CBarr virus (EBV)-positive B-cell model originating from a Burkitt’s lymphoma patient, notable for the t(8;14) chromosomal translocation causing constitutive MYC overexpression. These suspension-adapted cells are extensively employed to study B-cell receptor (BCR) signaling, apoptosis, and lymphomagenesis, making them an ideal host to dissect the roles of microtubule-based transport in malignant B lymphocytes.
DYNLT1 encodes Tctex-1, a core dynein light chain of the cytoplasmic dynein complex that drives minus-end-directed microtubule transport. DYNLT1 binds the dynein intermediate chain DYNC1I1 and interacts with the heavy chain DYNC1H1 and the dynactin complex, which links dynein to cargo via adaptors like BICD2 and TRAK1. Its activity is regulated by upstream factors including CDK1-mediated phosphorylation and cofactors NDEL1 and LIS1, which coordinate dynein function during mitosis and intracellular trafficking. Consequently, DYNLT1 disruption impairs retrograde transport, mitotic spindle assembly, and BCR signaling pathways.
In Raji B cells, DYNLT1 knockout is expected to impair retrograde transport essential for BCR internalization and signaling endosome maturation, potentially altering signal transduction dynamics. Dynein also positions the mitotic spindle; its loss may lead to mitotic defects and genomic instability, especially given MYC-driven high proliferation. This model thus facilitates dissection of dynein’s contributions to lymphomagenesis, cell cycle control, and drug sensitivity.
Enabling functional studies, these knockout cells are suitable for confirming DYNLT1 loss via immunoblotting and RT?qPCR, visualizing dynein mislocalization by immunofluorescence, and assessing mitotic defects through flow cytometry. Transcriptomic analysis by RNA?seq reveals downstream gene expression changes, while co?immunoprecipitation identifies altered dynein interactors. Functional assays for migration and invasion, along with drug sensitivity profiling using microtubule?targeting compounds, further extend their utility in lymphoma research and drug discovery. For specialized support, contact Ascent Research.
